Home » Topics » BioWorld Science

BioWorld Science
RSS

Ramoplanin granted orphan drug status in Europe

July 13, 2001

EntreMed begins enrollment of initial patients in phase I/II study of rhEndostatin

July 13, 2001

FTY-720: effects on lymphocytes and in animal models of autoimmune diseases

July 13, 2001

Cangene halts pilot phase II trial of anti-HCV hyperimmune product

July 13, 2001

Protective effect demonstrated for FR-167653 against aspirin-induced gastric damage

July 13, 2001

EMEA accepts Oxford GlycoSciences' MAA for Vevesca

July 13, 2001

Sea cucumber-based therapy useful for age-associated dementia

July 13, 2001

MabCampath approved in Europe for B-CLL

July 13, 2001

Lilly Icos seeks European approval of Cialis for treatment of erectile dysfunction

July 13, 2001

Safer anticoagulation obtained with Ro-67-8698, a new factor VIIa inhibitor, than napsagatran

July 13, 2001

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Jiangsu Nhwa Pharmaceutical patents new κ-opioid receptor antagonists
BioWorld Science
Jiangsu Nhwa Pharmaceutical Co. Ltd. has disclosed κ-opioid receptor antagonists that are potentially useful for the treatment of neurological disorders.